European Medicines Agency seeks more resources for future regulatory activities
This article was originally published in SRA
Moves are under way to help ensure that the European Medicines Agency has sufficient resources for regulatory activities over the coming years, amid concerns that it might not be able to fund its new responsibilities in areas such as pharmacovigilance and counterfeit medicines.
You may also be interested in...
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
Coronavirus Notebook: EU Publishes CureVac Vaccine Contract, AZ and Pfizer Under Attack Over Supply Cuts
The European Ombudsman has opened an inquiry regarding the disclosure of vaccine contracts with other companies, and the European Commission is planning a “sharing mechanism” for vaccines bought by EU member states.